单纯奥沙利铂-替吉奥化疗方案与化疗辅助西黄胶囊治疗晚期胃癌的疗效及对T细胞亚群、生存率及不良反应的影响

Chemotherapy with oxaliplatin and tegafur gimeracil oteracil potassium capsule versus oxaliplatin-assisted xihuang capsules in the treatment of patients with advanced gastric cancer and its effects on T cell subsets,survival rate and adverse reactions

目的探讨单纯奥沙利铂-替吉奥化疗方案与化疗辅助西黄胶囊治疗晚期胃癌的疗效及对T细胞亚群、生存率及不良反应的影响。方法选取84例胃癌晚期患者,按照随机数字表法将所有患者分为对照组和试验组。对照组患者均给予替吉奥和奥沙利铂进行化疗,试验组患者则在对照组的治疗基础上加用西黄胶囊进行辅助治疗。比较2组患者的T细胞亚群和KPS评分、临床疗效、不良反应发生率以及生存率等指标。结果试验组患者的总有效率为59.5%,显著高于对照组患者的38.1%(P<0.05);试验组患者的疾病控制率为78.6%,显著高于对照组患者的57.1%(P<0.05)。2组患者治疗前以及治疗后的KPS评分组间比较,差异均无统计学意义(P>0.05)。试验组患者治疗后4周的CD_3^+、CD_4^+、CD_4^+/CD_8^+显著高于治疗前1周(P<0.05)。试验组患者中出现Ⅲ~Ⅳ度不良反应的例数(1例)显著低于对照组患者(5例)(P<0.05)。试验组患者的1年半生存率和2年生存率分别为57.1%和40.5%,显著高于对照组患者的1年半生存率35.7%和2年生存率19.0%(P<0.05)。结论在替吉奥和奥沙利铂化疗的同时加用西黄胶囊进行辅助治疗,能够有效提高患者的免疫力和生存率,临床疗效佳且不良反应较低,值得推广使用。

Objective To investigate curative efficacy of chemotherapy with oxaliplatin and tegafur gimeracil oteracil potassium capsule versus oxaliplatin-assisted xihuang capsules in the treatment of advanced gastric cancer and its effects on T cell subsets,survival rate and adverse reaction.Methods A total of 84 patients with gastric cancer in our hospital were randomly divided into control group and test group according to random number table method,control group was given chemotherapy with oxaliplatin and tegafur gimeracil oteracil potassium capsule,and test group was additionally given adjuvant treatment of xihuang capsules on the basis of the control group. T cell subsets and KPS score,clinical efficacy,adverse reactions and survival rate were compared. Results The total effective rate in the test group was 59. 5%,which was significantly higher than 38. 1% in the control group（ P〈0. 05）. Disease control rate was 78. 6% in the test group,which was significantly higher than5 7. 1 % in the control group（ P〈0. 0 5）. The KPS scores showed no significant difference before and after treatment in two groups（ P〈0. 05）. The levels of CD3^＋,CD4^＋,and CD4^＋/CD8^＋ inthe experimental group at 4 weeks after treatment were significantly higher than that 1 week before treatment（ P〈0. 05）. Patients with adverse reactions for grade III or IV in the test group were significantly less than that in the control group（ 1 case vs. 5 cases,P〈0. 05）. One and a half year survival rate and 2-year survival rate in the test group were 57. 1% and 40. 5%,which were significantly higher than 35. 7%,19% in the control group（ P〈0. 05）. Conclusion Adjuvant therapy of xihuang capsules can effectively improve the immunity and survival rate,and reduce adverse reactions,so it is worthy of popularization in clinic.